IQ-AI Limited IB Trax(TM) (5309Y)
September 10 2020 - 2:00AM
UK Regulatory
TIDMIQAI
RNS Number : 5309Y
IQ-AI Limited
10 September 2020
IQ-AI Ltd
("IQ-AI" or the "Company")
IB Trax(TM) - the next evolution in brain cancer response
assessment
Further building upon its leading position in brain tumour
imaging, IQ-AI's subsidiary, Imaging Biometrics (IB), announces the
launch its next development initiative, IB Trax. This application
will leverage the proven ability of quantitative Delta T1 maps,
among other technologies, and focus on an improved workflow for
evaluating both brain metastases and primary brain cancer across
time. For almost a decade, IB's medical advisors and end-users of
IB Neuro have considered that the manually intensive way currently
used to longitudinally assess brain lesions is cumbersome and prone
to error. IB Trax represents an efficient and streamlined platform
that will address a significant and immediate need for routine
clinical use.
Metastatic brain tumours are the most common cancers occurring
in the brain and result from the spread of primary cancers from
sites such as lung, breast, melanoma, colon, and kidney. The
American Brain Tumor Association estimates the incidence of brain
metastases to be between 200,000 to 300,000 people per year in the
United States, approximately ten times the incidence of primary
brain tumours. In addition, 10 to 30 percent of people with cancer
develop metastatic brain tumours with most having multiple
metastases in the brain. Moreover, the overall incidence of
metastatic brain disease is increasing, paralleling the rise in
primary lung cancer, but also a result of the increased survival
rates in patients with metastases.
Key to the management of metastatic disease is the radiologist's
assessment of the initial extent of disease followed by routine
surveillance to determine if each individual lesion is changing in
size and/or if new lesions are present. This represents a
tremendous burden for radiologists, because of the frequency of
surveillance required, but also because there might exist numerous
metastases of various sizes, each changing in different ways over
time. The current approach is to manually identify each lesion and
then visually assess its growth over time while also keeping track
of which lesion(s) have already been assessed. This process is
performed for each of the hundreds of high-resolution MR image
slices obtained for each patient at each visit. Moreover, current
MRIs, and each lesion, must be compared to the MRIs obtained at
previous time points. Delta T1 maps, which improve sensitivity to
contrast agent enhancement and eliminate confounding signals, will
foster rapid and objective delineation of true enhancing regions
for radiologists.
Although not as common, high grade primary tumours introduce
unique challenges for radiologists. Specifically, new tumour growth
often mimics treatment effect on contrast enhanced images. For high
grade tumours, IB Trax will leverage the proven technology of IB
Neuro which is the only commercially available, tissue validated
perfusion method that answers the most important question in neuro
oncology today: "Is the enhancing region showing a tumour or is it
an effect due to treatment?"
IB is well-positioned to couple their existing technologies with
an improved workflow to systematically identify, quantify, and
track primary and metastatic brain lesions. This will reduce
measurement variability which should result in more timely
treatment decisions. Along with this novel approach for tracking
lesion volume, IB Trax will also incorporate traditional approaches
for tracking volumes, such as the RECIST criteria.
The Directors of the Company accept responsibility for the
contents of this announcement.
-ENDS-
For further information, please contact:
IQ-AI Limited
Trevor Brown/Vinod Kaushal/Qu Li
Tel: 020 7469 0930
----------------------------------------------------------
Peterhouse Capital Limited (Financial Adviser and Broker)
Lucy Williams/Heena Karani
Tel: 020 7220 9797
----------------------------------------------------------
ABOUT Imaging Biometrics , LLC
Imaging Biometrics(R), a subsidiary of IQ-AI Limited (LON:IQAI),
develops and provides visualisation and analytical solutions that
enable clinicians to better diagnose and treat disease with greater
confidence. Through close collaboration with top researchers and
clinicians, sophisticated advancements are translated into
platform-independent and automated software plug-ins which can
extend the base functionality of workstations, imaging systems,
PACS, or medical viewers. By design, IB's advanced visualisation
software seamlessly integrates into routine workflows. For more
information about Imaging Biometrics, visit the company's website
at www.imagingbiometrics.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
STRUKVVRRUUKRAR
(END) Dow Jones Newswires
September 10, 2020 02:00 ET (06:00 GMT)
Iq-ai (LSE:IQAI)
Historical Stock Chart
From Apr 2024 to May 2024
Iq-ai (LSE:IQAI)
Historical Stock Chart
From May 2023 to May 2024